Loading…
Agreement includes potential payments up to $1 billion and tiered royalties.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced on March 28, 2025, that it has entered into an exclusive license agreement with Novo Nordisk for the development and commercialization of LX9851. The agreement includes upfront and near-term milestone payments of up to $75 million and tiered royalties on net sales of LX9851.
The total potential payments under the agreement could reach up to $1 billion, contingent on the achievement of development, regulatory, and sales milestones. Lexicon Pharmaceuticals has a free float of 184,051,000 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.